Keyphrases
Optic Neuritis
100%
Targeted Agents
100%
Phase II Randomized Trial
100%
Atacicept
100%
B-cell Targeting
100%
Placebo
50%
Multiple Sclerosis
25%
Treatment Group
25%
Same Patient
12%
Clinically Isolated Syndrome
12%
Disease Activity
12%
Relapsing-remitting multiple Sclerosis
12%
Change from Baseline
12%
Twice Daily
12%
Mean Standard Deviation
12%
Clinically Definite multiple Sclerosis
12%
Treatment-related Adverse Events
12%
Retinal Nerve Fiber Layer Thickness (RNFLT)
12%
Once-weekly
12%
Loading Time
12%
Data Monitoring
12%
Axonal Loss
12%
Safety Monitoring
12%
Monitoring Boards
12%
Board Review
12%
Medicine and Dentistry
B Cell
100%
Optic Neuritis
100%
Atacicept
100%
Multiple Sclerosis
50%
Placebo
50%
Adverse Event
12%
Clinically Isolated Syndrome
12%
Disease Activity
12%
Retinal Nerve Fiber Layer
12%
Arm
12%
Pharmacology, Toxicology and Pharmaceutical Science
Optic Neuritis
100%
Atacicept
100%
Placebo
50%
Multiple Sclerosis
50%
Adverse Event
12%
Disease Activity
12%
Demyelinating Disease
12%